154 related articles for article (PubMed ID: 25677267)
1. First-line treatments for chronic lymphocytic leukaemia: interpreting efficacy data by network meta-analysis.
Messori A; Fadda V; Maratea D; Trippoli S
Ann Hematol; 2015 Jun; 94(6):1003-9. PubMed ID: 25677267
[TBL] [Abstract][Full Text] [Related]
2. A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia.
Ladyzynski P; Molik M; Foltynski P
Cancer Treat Rev; 2015 Feb; 41(2):77-93. PubMed ID: 25512118
[TBL] [Abstract][Full Text] [Related]
3. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
Eichhorst B; Fink AM; Bahlo J; Busch R; Kovacs G; Maurer C; Lange E; Köppler H; Kiehl M; Sökler M; Schlag R; Vehling-Kaiser U; Köchling G; Plöger C; Gregor M; Plesner T; Trneny M; Fischer K; Döhner H; Kneba M; Wendtner CM; Klapper W; Kreuzer KA; Stilgenbauer S; Böttcher S; Hallek M; ;
Lancet Oncol; 2016 Jul; 17(7):928-942. PubMed ID: 27216274
[TBL] [Abstract][Full Text] [Related]
4. Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG).
Cramer P; Isfort S; Bahlo J; Stilgenbauer S; Döhner H; Bergmann M; Stauch M; Kneba M; Lange E; Langerbeins P; Pflug N; Kovacs G; Goede V; Fink AM; Elter T; Fischer K; Wendtner CM; Hallek M; Eichhorst B
Haematologica; 2015 Nov; 100(11):1451-9. PubMed ID: 26315931
[TBL] [Abstract][Full Text] [Related]
5. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy of first-line therapies for advanced-stage chronic lymphocytic leukemia: a multiple-treatment meta-analysis.
Terasawa T; Trikalinos NA; Djulbegovic B; Trikalinos TA
Cancer Treat Rev; 2013 Jun; 39(4):340-9. PubMed ID: 22703832
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of First-line Chronic Lymphocytic Leukemia Treatments When Full-dose Fludarabine Is Unsuitable.
Soini E; Hautala A; Poikonen E; Becker U; Kyttälä M; Martikainen J
Clin Ther; 2016 Apr; 38(4):889-904.e14. PubMed ID: 26970696
[TBL] [Abstract][Full Text] [Related]
8. Fludarabine phosphate for the first-line treatment of chronic lymphocytic leukaemia.
Walker S; Palmer S; Erhorn S; Brent S; Dyker A; Ferrie L; Horsley W; Macfarlane K; White S; Thomas S
Health Technol Assess; 2009 Jun; 13 Suppl 1():35-40. PubMed ID: 19567212
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Vazquez ER; Spigel DR; Raefsky E; Bearden JD; Saez RA; Greco FA
Cancer; 2008 Mar; 112(6):1288-95. PubMed ID: 18189296
[TBL] [Abstract][Full Text] [Related]
10. Rituximab for the treatment of relapsed/refractory chronic lymphocytic leukaemia.
Dretzke J; Barton P; Kaambwa B; Connock M; Uthman O; Bayliss S; Meads C
Health Technol Assess; 2010 Oct; 14(Suppl. 2):19-26. PubMed ID: 21047487
[TBL] [Abstract][Full Text] [Related]
11. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.
Catovsky D; Richards S; Matutes E; Oscier D; Dyer M; Bezares RF; Pettitt AR; Hamblin T; Milligan DW; Child JA; Hamilton MS; Dearden CE; Smith AG; Bosanquet AG; Davis Z; Brito-Babapulle V; Else M; Wade R; Hillmen P; ;
Lancet; 2007 Jul; 370(9583):230-239. PubMed ID: 17658394
[TBL] [Abstract][Full Text] [Related]
12. Cost-utility analysis of venetoclax in combination with obinutuzumab as first-line treatment of chronic lymphocytic leukaemia in Spain.
Moreno-Martínez E; De la Serna-Torroba J; Escudero-Vilaplana V; Hernández-Rivas JÁ; Sánchez-Cuervo M; Sánchez-Hernández R
Farm Hosp; 2022 Apr; 46(3):121-132. PubMed ID: 36183205
[TBL] [Abstract][Full Text] [Related]
13. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).
Robak T; Jamroziak K; Gora-Tybor J; Stella-Holowiecka B; Konopka L; Ceglarek B; Warzocha K; Seferynska I; Piszcz J; Calbecka M; Kostyra A; Dwilewicz-Trojaczek J; Dmoszyñska A; Zawilska K; Hellmann A; Zdunczyk A; Potoczek S; Piotrowska M; Lewandowski K; Blonski JZ
J Clin Oncol; 2010 Apr; 28(11):1863-9. PubMed ID: 20212251
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness Model for Chemoimmunotherapy Options in Patients with Previously Untreated Chronic Lymphocytic Leukemia Unsuitable for Full-Dose Fludarabine-Based Therapy.
Becker U; Briggs AH; Moreno SG; Ray JA; Ngo P; Samanta K
Value Health; 2016 Jun; 19(4):374-82. PubMed ID: 27325329
[TBL] [Abstract][Full Text] [Related]
15. Comparative Efficacy of Acalabrutinib in Frontline Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis.
Davids MS; Waweru C; Le Nouveau P; Padhiar A; Singh G; Abhyankar S; Leblond V
Clin Ther; 2020 Oct; 42(10):1955-1974.e15. PubMed ID: 33032842
[TBL] [Abstract][Full Text] [Related]
16. Bendamustine versus chlorambucil for the first-line treatment of chronic lymphocytic leukemia in England and Wales: a cost-utility analysis.
Woods B; Hawkins N; Dunlop W; O'Toole A; Bramham-Jones S
Value Health; 2012; 15(5):759-70. PubMed ID: 22867787
[TBL] [Abstract][Full Text] [Related]
17. Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial.
Knauf WU; Lissitchkov T; Aldaoud A; Liberati AM; Loscertales J; Herbrecht R; Juliusson G; Postner G; Gercheva L; Goranov S; Becker M; Fricke HJ; Huguet F; Del Giudice I; Klein P; Merkle K; Montillo M
Br J Haematol; 2012 Oct; 159(1):67-77. PubMed ID: 22861163
[TBL] [Abstract][Full Text] [Related]
18. Long-term progression-free survival in patients with chronic lymphocytic leukemia treated with novel agents: An analysis based on indirect comparisons.
Messori A
Eur J Haematol; 2023 Jan; 110(1):60-66. PubMed ID: 36193009
[TBL] [Abstract][Full Text] [Related]
19. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial.
Elter T; Gercheva-Kyuchukova L; Pylylpenko H; Robak T; Jaksic B; Rekhtman G; Kyrcz-Krzemień S; Vatutin M; Wu J; Sirard C; Hallek M; Engert A
Lancet Oncol; 2011 Dec; 12(13):1204-13. PubMed ID: 21992852
[TBL] [Abstract][Full Text] [Related]
20. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
Rai KR; Peterson BL; Appelbaum FR; Kolitz J; Elias L; Shepherd L; Hines J; Threatte GA; Larson RA; Cheson BD; Schiffer CA
N Engl J Med; 2000 Dec; 343(24):1750-7. PubMed ID: 11114313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]